ANAPTYSBIO, INC. Operating Loss Carryforwards
ANAPTYSBIO, INC. (ANAB) had Operating Loss Carryforwards of $154.10 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes
us-gaap:OperatingLossCarryforwards · last filed 2026-03-03
- 2025-12-31: Operating Loss Carryforwards $154.10M.
| Period end | Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $154.10M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |